MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status

Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline

(2012) Brendan J.W. Miles et al.   CUAJ-Canadian Urological Association Journal

DNA hypermethylation of microRNA-34b/c has prognostic value for stage Ⅰ non-small cell lung cancer

(2011) Zhen Wang et al.   CANCER BIOLOGY & THERAPY

Secreted protein acidic and rich in cysteine-induced cellular senescence in colorectal cancers in response to irinotecan is mediated by P53

(2010) Justin M. Chan et al.   CARCINOGENESIS

Epigenetic inactivation of the miR-34a in hematological malignancies

(2010) C.S. Chim et al.   CARCINOGENESIS

Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer

(2010) Dmitri Lodygin et al.   CELL CYCLE

Interactions between DBC1 and SIRT1 are deregulated in breast cancer cells

(2010) Ja-Eun Kim et al.   CELL CYCLE

Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia

(2010) Olaf Merkel et al.   CELL CYCLE

MicroRNA-34a Perturbs B Lymphocyte Development by Repressing the Forkhead Box Transcription Factor Foxp1

(2010) Dinesh S. Rao et al.   IMMUNITY

Targeting microRNAs in cancer: rationale, strategies and challenges

(2010) Ramiro Garzon et al.   NATURE REVIEWS DRUG DISCOVERY

MicroRNA control of signal transduction

(2010) Masafumi Inui et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Combining Targeted Therapies: Practical Issues to Consider at the Bench and Bedside

(2010) J. Rodon et al.   ONCOLOGIST

miRNA-regulated expression of oncogenes and tumor suppressor genes in the cisplatin-inhibited growth of K562 cells

(2010) Xie   ONCOLOGY REPORTS

Molecular pathways of urothelial development and bladder tumorigenesis

(2010) Mireia Castillo-Martin et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

p53 expression in patients with advanced urothelial cancer of the urinary bladder

(2009) Shahrokh F. Shariat et al.   BJU INTERNATIONAL

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial

(2009) T. Zenz et al.   BLOOD

miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer

(2009) Elena Gallardo et al.   CARCINOGENESIS

p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC

(2009) N R Christoffersen et al.   CELL DEATH AND DIFFERENTIATION

The miR-34 family in cancer and apoptosis

(2009) H Hermeking   CELL DEATH AND DIFFERENTIATION

Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy

(2009) M. H. Kang et al.   CLINICAL CANCER RESEARCH

Reduced levels of miR-34a in neuroblastoma are not caused by mutations in theTP53binding site

(2009) Galina Feinberg-Gorenshtein et al.   GENES CHROMOSOMES & CANCER

p53 Predictive Value for pT1-2 N0 Disease at Radical Cystectomy

(2009) Shahrokh F. Shariat et al.   JOURNAL OF UROLOGY

LNA-mediated microRNA silencing in non-human primates

(2008) Joacim Elmén et al.   NATURE

In situ detection of precursor and mature microRNAs in paraffin embedded, formalin fixed tissues and cell preparations

(2007) Gerard J. Nuovo   METHODS